

Alfred Zippelius

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8106951/publications.pdf>

Version: 2024-02-01

127
papers

10,328
citations

53751

45
h-index

43868

91
g-index

131
all docs

131
docs citations

131
times ranked

16315
citing authors

#	ARTICLE	IF	CITATIONS
1	A transcriptionally and functionally distinct PD-1+ CD8+ T cell pool with predictive potential in non-small-cell lung cancer treated with PD-1 blockade. <i>Nature Medicine</i> , 2018, 24, 994-1004.	15.2	783
2	Successful Anti-PD-1 Cancer Immunotherapy Requires T Cell-Dendritic Cell Crosstalk Involving the Cytokines IFN- γ and IL-12. <i>Immunity</i> , 2018, 49, 1148-1161.e7.	6.6	639
3	RNA-Seq Signatures Normalized by mRNA Abundance Allow Absolute Deconvolution of Human Immune Cell Types. <i>Cell Reports</i> , 2019, 26, 1627-1640.e7.	2.9	590
4	Effector Function of Human Tumor-Specific CD8 T Cells in Melanoma Lesions: A State of Local Functional Tolerance. <i>Cancer Research</i> , 2004, 64, 2865-2873.	0.4	351
5	Four Functionally Distinct Populations of Human Effector-Memory CD8+ T Lymphocytes. <i>Journal of Immunology</i> , 2007, 178, 4112-4119.	0.4	347
6	CD36-mediated metabolic adaptation supports regulatory T cell survival and function in tumors. <i>Nature Immunology</i> , 2020, 21, 298-308.	7.0	326
7	Induction chemoradiation in stage IIIA/N2 non-small-cell lung cancer: a phase 3 randomised trial. <i>Lancet, The</i> , 2015, 386, 1049-1056.	6.3	316
8	Selective Survival of Naturally Occurring Human CD4+CD25+Foxp3+ Regulatory T Cells Cultured with Rapamycin. <i>Journal of Immunology</i> , 2007, 178, 320-329.	0.4	309
9	Progression of Lung Cancer Is Associated with Increased Dysfunction of T Cells Defined by Coexpression of Multiple Inhibitory Receptors. <i>Cancer Immunology Research</i> , 2015, 3, 1344-1355.	1.6	285
10	Acute heart failure due to autoimmune myocarditis under pembrolizumab treatment for metastatic melanoma. , 2015, 3, 11.		274
11	Association of Checkpoint Inhibitor-Induced Toxic Effects With Shared Cancer and Tissue Antigens in Non-Small Cell Lung Cancer. <i>JAMA Oncology</i> , 2019, 5, 1043.	3.4	266
12	Trastuzumab emtansine (T-DM1) renders HER2 ⁺ breast cancer highly susceptible to CTLA-4/PD-1 blockade. <i>Science Translational Medicine</i> , 2015, 7, 315ra188.	5.8	261
13	Disturbed mitochondrial dynamics in CD8+ TILs reinforce T cell exhaustion. <i>Nature Immunology</i> , 2020, 21, 1540-1551.	7.0	252
14	Self-associated molecular patterns mediate cancer immune evasion by engaging Siglecs on T cells. <i>Journal of Clinical Investigation</i> , 2018, 128, 4912-4923.	3.9	214
15	SAKK 16/14: Durvalumab in Addition to Neoadjuvant Chemotherapy in Patients With Stage IIIA(N2) Non-Small-Cell Lung Cancer—A Multicenter Single-Arm Phase II Trial. <i>Journal of Clinical Oncology</i> , 2021, 39, 2872-2880.	0.8	183
16	Tumor-targeted 4-1BB agonists for combination with T cell bispecific antibodies as off-the-shelf therapy. <i>Science Translational Medicine</i> , 2019, 11, .	5.8	178
17	Neoadjuvant chemotherapy and extrapleural pneumonectomy of malignant pleural mesothelioma with or without hemithoracic radiotherapy (SAKK 17/04): a randomised, international, multicentre phase 2 trial. <i>Lancet Oncology, The</i> , 2015, 16, 1651-1658.	5.1	170
18	Ex vivo characterization of human CD8+ T subsets with distinct replicative history and partial effector functions. <i>Blood</i> , 2003, 102, 1779-1787.	0.6	167

#	ARTICLE	IF	CITATIONS
19	Systemic inflammation in a melanoma patient treated with immune checkpoint inhibitorsâ€”an autopsy study. , 2016, 4, 13.		162
20	An ex vivo tumor fragment platform to dissect response to PD-1 blockade in cancer. Nature Medicine, 2021, 27, 1250-1261.	15.2	159
21	Antigenicity and immunogenicity of Melan-A/MART-1 derived peptides as targets for tumor reactive CTL in human melanoma. Immunological Reviews, 2002, 188, 81-96.	2.8	146
22	Hepatic stellate cells suppress NK cell-sustained breast cancer dormancy. Nature, 2021, 594, 566-571.	13.7	139
23	Thymic Selection Generates a Large T Cell Pool Recognizing a Self-Peptide in Humans. Journal of Experimental Medicine, 2002, 195, 485-494.	4.2	136
24	Ex Vivo IFN- γ Secretion by Circulating CD8 T Lymphocytes: Implications of a Novel Approach for T Cell Monitoring in Infectious and Malignant Diseases. Journal of Immunology, 2001, 166, 7634-7640.	0.4	135
25	Microtubule-Depolymerizing Agents Used in Antibodyâ€”Drug Conjugates Induce Antitumor Immunity by Stimulation of Dendritic Cells. Cancer Immunology Research, 2014, 2, 741-755.	1.6	134
26	Local Tumor Treatment in Combination with Systemic Ipilimumab Immunotherapy Prolongs Overall Survival in Patients with Advanced Malignant Melanoma. Cancer Immunology Research, 2016, 4, 744-754.	1.6	131
27	Phase Ib evaluation of a self-adjuvanted protamine formulated mRNA-based active cancer immunotherapy, BI1361849 (CV9202), combined with local radiation treatment in patients with stage IV non-small cell lung cancer. , 2019, 7, 38.		121
28	Induced PD-L1 Expression Mediates Acquired Resistance to Agonistic Anti-CD40 Treatment. Cancer Immunology Research, 2015, 3, 236-244.	1.6	117
29	A phase I/IIa study of the mRNA-based cancer immunotherapy CV9201 in patients with stage IIIB/IV non-small cell lung cancer. Cancer Immunology, Immunotherapy, 2019, 68, 799-812.	2.0	115
30	Influenza vaccination of cancer patients during PD-1 blockade induces serological protection but may raise the risk for immune-related adverse events. , 2018, 6, 40.		110
31	Phase Ib study evaluating a self-adjuvanted mRNA cancer vaccine (RNAActive ^Â) combined with local radiation as consolidation and maintenance treatment for patients with stage IV non-small cell lung cancer. BMC Cancer, 2014, 14, 748.	1.1	101
32	Siglec-9 Regulates an Effector Memory CD8+ T-cell Subset That Congregates in the Melanoma Tumor Microenvironment. Cancer Immunology Research, 2019, 7, 707-718.	1.6	94
33	Tumor mutational burden assessed by targeted NGS predicts clinical benefit from immune checkpoint inhibitors in nonâ€”small cell lung cancer. Journal of Pathology, 2020, 250, 19-29.	2.1	92
34	Degeneracy of Antigen Recognition as the Molecular Basis for the High Frequency of Naive A2/Melan-A Peptide Multimer+ CD8+ T Cells in Humans. Journal of Experimental Medicine, 2002, 196, 207-216.	4.2	90
35	Magnesium sensing via LFA-1 regulates CD8+ T cell effector function. Cell, 2022, 185, 585-602.e29.	13.5	83
36	Integrated Akt/PKB Signaling in Immunomodulation and Its Potential Role in Cancer Immunotherapy. Journal of the National Cancer Institute, 2015, 107, djv171-djv171.	3.0	78

#	ARTICLE	IF	CITATIONS
37	Prevalent Role of TCR $\hat{\pm}$ -Chain in the Selection of the Preimmune Repertoire Specific for a Human Tumor-Associated Self-Antigen. <i>Journal of Immunology</i> , 2003, 170, 5103-5109.	0.4	76
38	A novel anti-HER2 anthracycline-based antibody-drug conjugate induces adaptive anti-tumor immunity and potentiates PD-1 blockade in breast cancer. , 2019, 7, 16.		68
39	Adapted NOD/SCID model supports development of phenotypically and functionally mature T cells from human umbilical cord blood CD34+ cells. <i>Blood</i> , 2002, 99, 1620-1626.	0.6	66
40	Optimized antiangiogenic reprogramming of the tumor microenvironment potentiates CD40 immunotherapy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 541-551.	3.3	66
41	$\hat{\pm}$ 3 Domain Mutants of Peptide/MHC Class I Multimers Allow the Selective Isolation of High Avidity Tumor-Reactive CD8 T Cells. <i>Journal of Immunology</i> , 2003, 171, 1844-1849.	0.4	65
42	NY-ESO-1 protein expression in primary breast carcinoma and metastasesâ€™ correlation with CD8+ T-cell and CD79a+ plasmacytic/B-cell infiltration. <i>International Journal of Cancer</i> , 2007, 120, 2411-2417.	2.3	65
43	Cerebral vasculitis mimicking intracranial metastatic progression of lung cancer during PD-1 blockade. , 2017, 5, 46.		64
44	The T cell repertoire in tumors overlaps with pulmonary inflammatory lesions in patients treated with checkpoint inhibitors. <i>Oncolmmunology</i> , 2018, 7, e1386362.	2.1	62
45	Replicating viral vector platform exploits alarmin signals for potent CD8+ T cell-mediated tumour immunotherapy. <i>Nature Communications</i> , 2017, 8, 15327.	5.8	61
46	Tumor-derived TGF- $\hat{2}$ inhibits mitochondrial respiration to suppress IFN- $\hat{3}$ production by human CD4 ⁺ T cells. <i>Science Signaling</i> , 2019, 12, .	1.6	61
47	High Frequency of Functionally Active Melan-Aâ€™Specific T Cells in a Patient with Progressive Immunoproteasome-Deficient Melanoma. <i>Cancer Research</i> , 2004, 64, 6319-6326.	0.4	60
48	The microtubule-depolymerizing agent ansamitocin P3 programs dendritic cells toward enhanced anti-tumor immunity. <i>Cancer Immunology, Immunotherapy</i> , 2014, 63, 925-938.	2.0	60
49	Tumor-associated carbohydrates and immunomodulatory lectins as targets for cancer immunotherapy. , 2020, 8, e001222.		60
50	PD-1+ natural killer cells in human non-small cell lung cancer can be activated by PD-1/PD-L1 blockade. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 1505-1517.	2.0	58
51	Heterogeneous expression of MAGE-A genes in occult disseminated tumor cells: a novel multimarker reverse transcription-polymerase chain reaction for diagnosis of micrometastatic disease. <i>Cancer Research</i> , 2002, 62, 251-61.	0.4	55
52	Uncoupling protein 2 reprograms the tumor microenvironment to support the anti-tumor immune cycle. <i>Nature Immunology</i> , 2019, 20, 206-217.	7.0	51
53	Identification of tumor antigens as potential target antigens for immunotherapy by serological expression cloning. <i>Cancer Immunology, Immunotherapy</i> , 2004, 53, 144-147.	2.0	48
54	Immune checkpoints programmed death 1 ligand 1 and cytotoxic T lymphocyte associated molecule 4 in gastric adenocarcinoma. <i>Oncolmmunology</i> , 2016, 5, e1100789.	2.1	45

#	ARTICLE	IF	CITATIONS
55	Antisense oligonucleotide targeting CD39 improves anti-tumor T cell immunity. , 2019, 7, 67.		43
56	The multi-receptor inhibitor axitinib reverses tumor-induced immunosuppression and potentiates treatment with immune-modulatory antibodies in preclinical murine models. Cancer Immunology, Immunotherapy, 2018, 67, 815-824.	2.0	42
57	MALDI Detection of Exosomes: A Potential Tool for Cancer Studies. CheM, 2019, 5, 1318-1336.	5.8	42
58	GEF-H1 Signaling upon Microtubule Destabilization Is Required for Dendritic Cell Activation and Specific Anti-tumor Responses. Cell Reports, 2019, 28, 3367-3380.e8.	2.9	37
59	Activation of human melanoma reactive CD8+ T cells by vaccination with an immunogenic peptide analog derived from Melan-A/melanoma antigen recognized by T cells-1. Clinical Cancer Research, 2003, 9, 669-77.	3.2	37
60	Fibroblast activation protein-targeted-4-1BB ligand agonist amplifies effector functions of intratumoral T cells in human cancer. , 2020, 8, e000238.		35
61	Metastatic spread in patients with non-small cell lung cancer is associated with a reduced density of tumor-infiltrating T cells. Cancer Immunology, Immunotherapy, 2016, 65, 1-11.	2.0	34
62	Modulation of APC Function and Anti-Tumor Immunity by Anti-Cancer Drugs. Frontiers in Immunology, 2015, 6, 501.	2.2	33
63	Hyperglycemia Enhances Cancer Immune Evasion by Inducing Alternative Macrophage Polarization through Increased O-GlcNAcylation. Cancer Immunology Research, 2020, 8, 1262-1272.	1.6	32
64	A Variant of a Killer Cell Immunoglobulin-like Receptor Is Associated with Resistance to PD-1 Blockade in Lung Cancer. Clinical Cancer Research, 2019, 25, 3026-3034.	3.2	29
65	NK cells with tissue-resident traits shape response to immunotherapy by inducing adaptive antitumor immunity. Science Translational Medicine, 2022, 14, .	5.8	29
66	Tertiary Lymphoid Structures as a Predictive Biomarker of Response to Cancer Immunotherapies. Frontiers in Immunology, 2021, 12, 674565.	2.2	28
67	High frequencies of functionally impaired cytokeratin 18-specific CD8+ T cells in healthy HLA-A2+ donors. European Journal of Immunology, 2005, 35, 2876-2885.	1.6	27
68	Modified tumour antigen-encoding mRNA facilitates the analysis of naturally occurring and vaccine-induced CD4 and CD8 T cells in cancer patients. Cancer Immunology, Immunotherapy, 2009, 58, 325-338.	2.0	27
69	Grover's-like drug eruption in a patient with metastatic melanoma under ipilimumab therapy. , 2016, 4, 47.		27
70	Expression of inhibitory receptors on intratumoral T cells modulates the activity of a T cell-bispecific antibody targeting folate receptor. Oncoimmunology, 2016, 5, e1062969.	2.1	27
71	Clinical experience with combination BRAF/MEK inhibitors for melanoma with brain metastases: a real-life multicenter study. Melanoma Research, 2019, 29, 65-69.	0.6	27
72	SACK 16/14: Anti-PD-L1 antibody durvalumab in addition to neoadjuvant chemotherapy in patients with stage IIIA(N2) non-small cell lung cancer (NSCLC) – A multicenter single-arm phase II trial.. Journal of Clinical Oncology, 2020, 38, 9016-9016.	0.8	27

#	ARTICLE	IF	CITATIONS
73	Second-Line Therapy of Small-Cell Lung Cancer: Topotecan Compared to a Combination Treatment with Adriamycin, Cyclophosphamide And Vincristine (ACO) - a Single Center Experience. <i>Journal of Cancer</i> , 2015, 6, 1148-1154.	1.2	26
74	Spontaneous CD8 T Cell Responses against the Melanocyte Differentiation Antigen RAB38/NY-MEL-1 in Melanoma Patients. <i>Journal of Immunology</i> , 2006, 177, 8212-8218.	0.4	24
75	Vemurafenib-Induced Radiation Recall Dermatitis: Case Report and Review of the Literature. <i>Dermatology</i> , 2015, 230, 1-4.	0.9	23
76	Incidence and predictors of Bone Metastases (BM) and Skeletal-Related Events (SREs) in Small Cell Lung Cancer (SCLC): A Swiss patient cohort. <i>Journal of Cancer</i> , 2016, 7, 2110-2116.	1.2	23
77	Immunotherapy in head and neck cancer – scientific rationale, current treatment options and future directions. <i>Swiss Medical Weekly</i> , 2018, 148, w14625.	0.8	23
78	Ex Vivo Characterization of Allo-MHC-Restricted T Cells Specific for a Single MHC-Peptide Complex. <i>Journal of Immunology</i> , 2006, 176, 2330-2336.	0.4	22
79	iMATCH: an integrated modular assembly system for therapeutic combination high-capacity adenovirus gene therapy. <i>Molecular Therapy - Methods and Clinical Development</i> , 2021, 20, 572-586.	1.8	21
80	mTORC1/autophagy-regulated MerTK in mutant BRAFV600 melanoma with acquired resistance to BRAF inhibition. <i>Oncotarget</i> , 2017, 8, 69204-69218.	0.8	21
81	Denosumab treatment is associated with the absence of circulating tumor cells in patients with breast cancer. <i>Breast Cancer Research</i> , 2018, 20, 141.	2.2	20
82	Human Thymus Exports Naive CD8 T Cells That Can Home to Nonlymphoid Tissues. <i>Journal of Immunology</i> , 2004, 172, 2773-2777.	0.4	19
83	Carboplatin and Paclitaxel Plus ASA404 as First-Line Chemotherapy for Extensive-Stage Small-Cell Lung Cancer: A Multicenter Single Arm Phase II Trial (SAKK 15/08). <i>Clinical Lung Cancer</i> , 2013, 14, 34-39.	1.1	19
84	Cancer chemotherapy agents target intratumoral dendritic cells to potentiate antitumor immunity. <i>OncImmunology</i> , 2014, 3, e954460.	2.1	19
85	Treatment of mycophenolate-resistant immune-related organizing pneumonia with infliximab. , 2018, 6, 85.		19
86	Plinabulin, a Distinct Microtubule-Targeting Chemotherapy, Promotes M1-Like Macrophage Polarization and Anti-tumor Immunity. <i>Frontiers in Oncology</i> , 2021, 11, 644608.	1.3	19
87	Cetuximab in Metastatic Squamous Cell Cancer of the Skin: A Swiss Case Series. <i>Dermatology</i> , 2014, 229, 97-101.	0.9	18
88	Cancer immunology – development of novel anti-cancer therapies. <i>Swiss Medical Weekly</i> , 2015, 145, w14066.	0.8	18
89	Melanocyte differentiation antigen RAB38/NY-MEL-1 induces frequent antibody responses exclusively in melanoma patients. <i>Cancer Immunology, Immunotherapy</i> , 2006, 56, 249-258.	2.0	17
90	Therapeutic efficacy of the F8-IL2 immunocytokine in a metastatic mouse model of lung adenocarcinoma. <i>Lung Cancer</i> , 2015, 88, 9-15.	0.9	16

#	ARTICLE	IF	CITATIONS
91	Targeting Insulin-Like Growth Factor-I and Extracellular Matrix Interactions in Melanoma Progression. <i>Scientific Reports</i> , 2018, 8, 583.	1.6	16
92	Heterologous arenavirus vector prime-boost overrules self-tolerance for efficient tumor-specific CD8 T cell attack. <i>Cell Reports Medicine</i> , 2021, 2, 100209.	3.3	16
93	Siglec Receptors Modulate Dendritic Cell Activation and Antigen Presentation to T Cells in Cancer. <i>Frontiers in Cell and Developmental Biology</i> , 2022, 10, 828916.	1.8	16
94	Steatosis Hepatis in Celiac Disease. <i>Journal of Hepatology</i> , 1999, 30, 531.	1.8	15
95	Culture and Drug Profiling of Patient Derived Malignant Pleural Effusions for Personalized Cancer Medicine. <i>PLoS ONE</i> , 2016, 11, e0160807.	1.1	15
96	A multimarker real-time RT-PCR for MAGE-A gene expression allows sensitive detection and quantification of the minimal systemic tumor load in patients with localized cancer. <i>Journal of Immunological Methods</i> , 2007, 323, 180-193.	0.6	14
97	Bevacizumab, Pemetrexed, and Cisplatin, or Bevacizumab and Erlotinib for Patients With Advanced Non-Small-Cell Lung Cancer Stratified by Epidermal Growth Factor Receptor Mutation: Phase II Trial SAKK19/09. <i>Clinical Lung Cancer</i> , 2015, 16, 358-365.	1.1	14
98	Humanized Monoclonal Antibody Blocking Carbonic Anhydrase 12 Enzymatic Activity Leads to Reduced Tumor Growth <i>In Vitro</i> . <i>Anticancer Research</i> , 2019, 39, 4117-4128.	0.5	14
99	Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Maintenance Therapy for Patients With Advanced Nonsquamous Non-Small-cell Lung Cancer: Update From the Swiss Group for Clinical Cancer Research (SAKK) 19/09 Trial. <i>Clinical Lung Cancer</i> , 2017, 18, 303-309.	1.1	13
100	Resection of isolated brain metastases in non-small cell lung cancer (NSCLC) patients – evaluation of outcome and prognostic factors: A retrospective multicenter study. <i>PLoS ONE</i> , 2021, 16, e0253601.	1.1	13
101	Solid cancer development in solid organ transplant recipients within the Swiss Transplant Cohort Study. <i>Swiss Medical Weekly</i> , 2019, 149, w20078.	0.8	11
102	Effects of COVID-19 Lockdown on Melanoma Diagnosis in Switzerland: Increased Tumor Thickness in Elderly Females and Shift towards Stage IV Melanoma during Lockdown. <i>Cancers</i> , 2022, 14, 2360.	1.7	10
103	Messenger RNA vaccination and B-cell responses in NSCLC patients. <i>Journal of Clinical Oncology</i> , 2012, 30, 2573-2573.	0.8	9
104	Neoadjuvant chemotherapy with or without preoperative irradiation in stage IIIA/N2 non-small cell lung cancer (NSCLC): A randomized phase III trial by the Swiss Group for Clinical Cancer Research (SAKK trial 16/00). <i>Journal of Clinical Oncology</i> , 2013, 31, 7503-7503.	0.8	9
105	A highly efficient modality to block the degradation of tryptophan for cancer immunotherapy: locked nucleic acid-modified antisense oligonucleotides to inhibit human indoleamine 2,3-dioxygenase 1/tryptophan 2,3-dioxygenase expression. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 57-67.	2.0	6
106	Immune response and adverse events to influenza vaccine in cancer patients undergoing PD-1 blockade. <i>Journal of Clinical Oncology</i> , 2017, 35, e14523-e14523.	0.8	6
107	Therapeutic Targeting of Golgi Phosphoprotein 2 (GOLPH2) with Armed Antibodies: A Preclinical Study of Anti-GOLPH2 Antibody Drug Conjugates in Lung and Colorectal Cancer Models of Patient Derived Xenografts (PDX). <i>Targeted Oncology</i> , 2019, 14, 577-590.	1.7	4
108	Immune tumor board: integral part in the multidisciplinary management of cancer patients treated with cancer immunotherapy. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2019, 474, 485-495.	1.4	3

#	ARTICLE	IF	CITATIONS
109	SAKK 16/14: Anti-PD-L1 antibody durvalumab (MEDI4736) in addition to neoadjuvant chemotherapy in patients with stage IIIA(N2) non-small cell lung cancer (NSCLC)â€”A multicenter single-arm phase II trial.. Journal of Clinical Oncology, 2018, 36, TPS8584-TPS8584.	0.8	3
110	Toxicity associated with PD-1 blockade after allogeneic haematopoietic cell transplantation. Swiss Medical Weekly, 2019, 149, w20150.	0.8	3
111	FDG PET/CT Imaging of a Gastric Fistula. Clinical Nuclear Medicine, 2007, 32, 336-337.	0.7	2
112	Cancer immunology, inflammation, and tolerance: an introduction. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2019, 474, 405-406.	1.4	2
113	Validation of Pretreatment Prognostic Factors and Prognostic Staging Systems for Small Cell Lung Cancer in a Real-World Data Set. Cancers, 2022, 14, 2625.	1.7	2
114	P3.02c-091 Final Phase Ib Results of RNAActiveÂ® Cancer Vaccine BI 1361849 and Local Radiation as Maintenance Therapy for Stage IV NSCLC. Journal of Thoracic Oncology, 2017, 12, S1333-S1334.	0.5	1
115	Current and future developments of immunotherapy in lung cancer. Memo - Magazine of European Medical Oncology, 2018, 11, 122-131.	0.3	1
116	Tumor mutational burden assessed by a targeted NGS assay to predict clinical benefit from immune checkpoint inhibitors in non-small cell lung cancer.. Journal of Clinical Oncology, 2019, 37, e14266-e14266.	0.8	1
117	Agonistic anti-CD40 therapy synergizes with LAG-3-blocking antibodies. International Journal of Clinical Pharmacology and Therapeutics, 2017, 55, 692-694.	0.3	1
118	SAKK 16/14: Anti-PD-L1 antibody durvalumab (MEDI4736) in addition to neoadjuvant chemotherapy in patients with stage IIIA(N2) non-small cell lung cancer (NSCLC)â€”A multicenter single-arm phase II trial.. Journal of Clinical Oncology, 2016, 34, TPS8573-TPS8573.	0.8	1
119	Endotoxin and asthma. New England Journal of Medicine, 2003, 348, 171-4; author reply 171-4.	13.9	1
120	Follow-up in non-small-cell lung cancer. Memo - Magazine of European Medical Oncology, 2014, 7, 97-101.	0.3	0
121	PUB041 HGF, VEGFA and ANGPT2 Predict Clinical Benefit from Bevacizumab and Chemotherapy in Patients with Advanced NSCLC (SAKK19/09). Journal of Thoracic Oncology, 2017, 12, S1471.	0.5	0
122	P1.07-041 Validation of Prognostic Scores in Small Cell Lung Cancer. Journal of Thoracic Oncology, 2017, 12, S721-S722.	0.5	0
123	Stage dependent increase of CCL2 and CCL5 in peripheral blood of colorectal cancer patients.. Journal of Clinical Oncology, 2015, 33, e22111-e22111.	0.8	0
124	Tumor mutational burden assessed by a targeted NGS assay to predict benefit from immune checkpoint inhibitors in non-small cell lung cancer.. Journal of Clinical Oncology, 2018, 36, e15075-e15075.	0.8	0
125	Arenavirus-based vector platform for massive tumor self-antigen-specific CD8 T cell immunity.. Journal of Clinical Oncology, 2019, 37, e14297-e14297.	0.8	0
126	Blocking LILRB and KIR receptors by B57 open conformers induces potent antitumor activity and acts synergistically with checkpoint blockade inhibition.. Journal of Clinical Oncology, 2019, 37, e14137-e14137.	0.8	0

#	ARTICLE	IF	CITATIONS
127	Abstract 4149: Knock-down of Neuropilin-1 by locked nucleic acid antisense oligonucleotides facilitates cancer immune control. Cancer Research, 2022, 82, 4149-4149.	0.4	0